BE/BA Studies
Accelerating Your Path to Market with Proven Expertise
With extensive experience in Phase I and Bioequivalence/Bioavailability (BE/BA) studies, supporting generic and super-generic 505(B)(2) development programs. Triumpharma is your trusted partner for navigating complex clinical evaluations. Experienced with relative bioavailability, bridging, and comparative PK studies, selected based on product characteristics and regulatory strategy.
Our scientifically rigorous data seamlessly supports global market submissions across the USA, Europe, Canada, Asia, and the MENA region. We provide comprehensive study execution for biotech products, biosimilars, super-generics, and small molecules across a diverse array of formulations, including long-acting injectables, inhalers, and transdermal patches.
Specific Study Capabilities & Deliverables:
- Fasting and fed condition studies
- Single and Multiple dose evaluations
- Dose-Proportionality assessments
- Drug-Drug Interaction (DDI) studies
- Specialized trials for narcotic and light-sensitive drugs
- Short to long confinement study management
- Oral inhalation studies
